Mauro Scala , María del Rocío González Soltero , Alberto Bellido Esteban , José Miguel Biscaia Fernández , Verónica Romero-Ferreiro , Alessandro Serretti , Giuseppe Fanelli , Roberto Rodriguez-Jimenez
{"title":"Oropharyngeal microbiota in patients with psychotic disorders: A scoping review on compositional and functional alterations","authors":"Mauro Scala , María del Rocío González Soltero , Alberto Bellido Esteban , José Miguel Biscaia Fernández , Verónica Romero-Ferreiro , Alessandro Serretti , Giuseppe Fanelli , Roberto Rodriguez-Jimenez","doi":"10.1016/j.pnpbp.2025.111288","DOIUrl":null,"url":null,"abstract":"<div><h3>Backgrounds</h3><div>Oropharyngeal microbiota may be implicated in the onset and progression of psychotic disorders. This scoping review aims to map the existing evidence concerning the composition, diversity, and metabolic pathways of the oropharyngeal microbiota in patients aged 18 to 65 with a main diagnosis of a psychotic disorder, including individuals at clinical high-risk for psychosis (CHR<img>P) or experiencing first episode psychosis (FEP).</div></div><div><h3>Methods</h3><div>The scoping review was performed according to the PRISMA-ScR checklist. The systematic literature search was conducted using PubMed, Web of Science, and CINAHL until February 2024.</div></div><div><h3>Results</h3><div>Seven cross-sectional studies were included, comprising 43 individuals at CHR<img>P, 13 with FEP, 85 with first-episode of schizophrenia (FES), 171 with schizophrenia, and 8 with another schizophrenia spectrum disorder. The oropharyngeal microbiota showed an increase in <em>Lactobacillus gasseri</em> abundance in schizophrenia, and in <em>Firmicutes/Proteobacteria</em> phylum ratio in patients experiencing CHR-P and FES. In schizophrenia, an altered β-diversity was observed alongside increased metabolic pathways related to metabolite transporters. In FES, higher α-diversity and disruptions in amino acid, carbohydrate, and xenobiotic metabolism pathways were found. Hydrogen sulfide (H<sub>2</sub>S)-producing bacteria were generally enriched in all the stages of disease. Correlations were observed between oropharyngeal microbiota and psychotic symptom domains.</div></div><div><h3>Conclusions</h3><div>Potential microbial signatures, such as <em>Lactobacillus gasseri</em> and H<sub>2</sub>S-producing bacteria, were identified in the oropharyngeal microbiota. Alterations in the oropharyngeal microbiota composition and function may be associated with different stages of psychotic disorders, with some overlap between CHR-P and FES.</div></div>","PeriodicalId":54549,"journal":{"name":"Progress in Neuro-Psychopharmacology & Biological Psychiatry","volume":"137 ","pages":"Article 111288"},"PeriodicalIF":3.9000,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Progress in Neuro-Psychopharmacology & Biological Psychiatry","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0278584625000429","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Backgrounds
Oropharyngeal microbiota may be implicated in the onset and progression of psychotic disorders. This scoping review aims to map the existing evidence concerning the composition, diversity, and metabolic pathways of the oropharyngeal microbiota in patients aged 18 to 65 with a main diagnosis of a psychotic disorder, including individuals at clinical high-risk for psychosis (CHRP) or experiencing first episode psychosis (FEP).
Methods
The scoping review was performed according to the PRISMA-ScR checklist. The systematic literature search was conducted using PubMed, Web of Science, and CINAHL until February 2024.
Results
Seven cross-sectional studies were included, comprising 43 individuals at CHRP, 13 with FEP, 85 with first-episode of schizophrenia (FES), 171 with schizophrenia, and 8 with another schizophrenia spectrum disorder. The oropharyngeal microbiota showed an increase in Lactobacillus gasseri abundance in schizophrenia, and in Firmicutes/Proteobacteria phylum ratio in patients experiencing CHR-P and FES. In schizophrenia, an altered β-diversity was observed alongside increased metabolic pathways related to metabolite transporters. In FES, higher α-diversity and disruptions in amino acid, carbohydrate, and xenobiotic metabolism pathways were found. Hydrogen sulfide (H2S)-producing bacteria were generally enriched in all the stages of disease. Correlations were observed between oropharyngeal microbiota and psychotic symptom domains.
Conclusions
Potential microbial signatures, such as Lactobacillus gasseri and H2S-producing bacteria, were identified in the oropharyngeal microbiota. Alterations in the oropharyngeal microbiota composition and function may be associated with different stages of psychotic disorders, with some overlap between CHR-P and FES.
背景:口咽微生物群可能与精神障碍的发生和发展有关。本综述旨在对18 - 65岁主要诊断为精神障碍的患者(包括临床精神病高危人群(CHRP)或首发精神病(FEP)患者)口咽微生物群的组成、多样性和代谢途径的现有证据进行梳理。方法:根据PRISMA-ScR检查表进行范围审查。系统的文献检索使用PubMed, Web of Science和CINAHL进行,直到2024年2月。结果:纳入了7项横断面研究,包括43名CHRP患者,13名FEP患者,85名首发精神分裂症患者(FES), 171名精神分裂症患者和8名其他精神分裂症谱系障碍患者。口咽部微生物群显示精神分裂症患者的乳酸杆菌丰度增加,CHR-P和FES患者的厚壁菌门/变形菌门比例增加。在精神分裂症中,观察到β-多样性的改变以及与代谢物转运蛋白相关的代谢途径的增加。在FES中发现了更高的α-多样性和氨基酸、碳水化合物和外源代谢途径的破坏。产生硫化氢(H2S)的细菌在疾病的所有阶段普遍富集。观察到口咽微生物群与精神病症状域之间的相关性。结论:在口咽菌群中发现了潜在的微生物特征,如气态乳杆菌和产生h2s的细菌。口咽菌群组成和功能的改变可能与精神障碍的不同阶段有关,chrp和FES之间有一些重叠。
期刊介绍:
Progress in Neuro-Psychopharmacology & Biological Psychiatry is an international and multidisciplinary journal which aims to ensure the rapid publication of authoritative reviews and research papers dealing with experimental and clinical aspects of neuro-psychopharmacology and biological psychiatry. Issues of the journal are regularly devoted wholly in or in part to a topical subject.
Progress in Neuro-Psychopharmacology & Biological Psychiatry does not publish work on the actions of biological extracts unless the pharmacological active molecular substrate and/or specific receptor binding properties of the extract compounds are elucidated.